Your selections:
Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment
- Van Zyl, Belinda, Tang, Denise, Bowden, Nikola A.
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
- Wagner, U., Marth, C., Gebski, V., Lauraine, E. P., Largillier, R., Kaern, J., Brown, C., Heywood, M., Bonaventura, T., Vergote, I., Piccirillo, M. C., Fossati, R.
Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy?
Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy
- Wong-Brown, Michelle W., van der Westhuizen, Andre, Bowden, Nikola A.
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
- Budden, Timothy, van der Westhuizen, Andre, Bowden, Nikola A.
The role of nucleotide excision repair in melanoma development and platinum chemotherapy resistance
Are you sure you would like to clear your session, including search history and login status?